Clinical Trial Update: Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety of switching from donepezil to rivastigmine patch in patients with probable Alzheimer's disease; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Aricept (Donepezil)
• Exelon Patch (rivastigmine transdermal patch)

Snippet

Sponsor: Novartis | Conditions: Alzheimer's Disease | Phase 3 | Status: COMPLETED | Results posted: 2011-06-27